Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Supportive and palliative care 1

5270 - Physical activity (PA) and patterns of quality of life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC)


20 Oct 2018


Poster Discussion session - Supportive and palliative care 1


Supportive Care and Symptom Management

Tumour Site

Breast Cancer


Antonio Di Meglio


A. Di Meglio1, M. El-Mouhebb2, S. Michiels3, D. Carene1, S. Everhard4, A.L. Martin5, P.H. Cottu6, F. Lerebours7, C. Coutant8, A. Lesur9, O. Tredan10, P. Soulie11, L. Vanlemmens12, P. Arveux8, S. Delaloge13, P. Ganz14, F. André15, A.H. Partridge16, L. Jones17, I. Vaz-Luis1

Author affiliations

  • 1 Medical Oncology, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 2 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 3 Team Oncostat, Cesp, Gustave Roussy, 94805 - Villejuif/FR
  • 4 Ucbg, UNICANCER, 75654 - Paris/FR
  • 5 Research & Develpment, Unicancer, 75654 - Paris/FR
  • 6 Medical Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 7 Medical Oncology, Institut Curie Saint Cloud, 92210 - Saint Cloud/FR
  • 8 Medical Oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 9 Medical Oncology, Institut de cancérologie de Lorraine, 54519 - Nancy/FR
  • 10 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 11 Medical Oncology, Centre Paul Papin, 49055 - Angers/FR
  • 12 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 13 Medical Oncology, Gustave Roussy, 94805 - Villejuif/FR
  • 14 Medical Oncology, UCLA, 90095 - Los Angeles/US
  • 15 Medical Oncology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 16 Medical Oncology, Dana-Farber Cancer Institute, MA 02215, - Boston/US
  • 17 Exercise Oncology Research Program, Memorial Sloan Kettering Cancer Center, New York/US

Abstract 5270


We aimed to describe longitudinal patterns of QOL and the interplay between PA and risk of QOL deterioration among BC patients (pts).


We used a French prospective longitudinal clinical study (CANTO, NCT01993498) to identify 2525 stage I-III BC pts treated with adjuvant CT from 2012-14. PA exposure (GPAQ 16) and QOL (EORTC QLQ C30/B23) were reported by pts before CT, and at 3-6 and 12 months after CT. Pts with levels of PA ≥10 MET-hours/week were considered physically active (as per WHO recommendations on PA). Poor QOL was defined by functional scores <60 and symptoms scores ≥40 (Giesinger, 2016). We used multivariate mixed models to assess patterns of QOL and group based trajectory models to identify clusters of pts with poor QOL and associated risk factors, adjusting for PA as time dependent covariate.


Mean age (Standard Deviation, SD) was 52 y (11). 57%, 62% and 63% pts were physically active before CT, 3-6 and 12 months after CT, respectively. QOL scores before CT were higher among physically active vs inactive pts, including (mean [SD]): global health status (GHS) (69 [1.4] vs 65 [1.4]), physical (90 [1.1] vs 87 [1.1]) and emotional function (65 [1.9] vs 62 [1.9]) (all adjusted p<.05). QOL significantly worsened after CT, but scores remained higher among active pts (p<.001). A cluster of 33% pts had high and persistent risk of poor GHS: associated factors included comorbidities vs no (adjusted odds ratio 1.4 [95% Confidence Interval 1.1-1.9]), low income vs high (1.6 [1.2-2.0]), smoking vs no (1.3 [1.1-1.6]), mastectomy vs partial surgery (1.2 [1.1-1.6]). A significant interaction between recommended levels of PA and risk of poor GHS was observed (p<.001). Consistent with GHS, we found clusters of pts with high risk of poor QOL across physical, emotional and multiple other QOL domains, with similar risk factors and significant interactions with recommended levels of PA.


Among this large cohort of BC survivors, QOL significantly worsened after CT. We were able to group pts following distinct longitudinal patterns of QOL and to identify clinical, socio-economical, and treatment risk factors for poor QOL, including PA behavior. Interventional strategies that also promote PA may help prevent QOL deterioration after CT.

Clinical trial identification


Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.